Journal of Clinical Oncology, Vol 10, 635-643, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Combined modality therapy for primary CNS lymphoma

LM DeAngelis, J Yahalom, HT Thaler and U Kher
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

PURPOSE: Primary CNS lymphoma (PCNSL), formerly rare, is being seen with increased frequency among apparently immunocompetent patients. Conventional treatment has consisted of whole-brain radiotherapy (RT) and corticosteroids, with a median survival of 15 to 18 months and a 3% to 4% 5-year survival. Chemotherapy has been useful in the treatment of recurrent PCNSL. In 1985 we began a treatment protocol using chemotherapy and cranial irradiation for the initial therapy of non- AIDS PCNSL. PATIENTS AND METHODS: Thirty-one patients (group A) completed the combined modality regimen. All had placement of an Ommaya reservoir and received pre-RT systemic methotrexate, 1 g/m2, plus six doses of intra-Ommaya methotrexate at 12 mg per dose. A full course of cranial RT (4,000-cGy whole-brain RT plus a 1,440-cGy boost) was followed by two cycles of high-dose cytarabine (ara-C), with each course consisting of two doses of 3 g/m2 ara-C separated by 24 hours and infused over 3 hours. During this period, 16 additional patients (group R) were treated with RT alone, either because patients refused chemotherapy or RT was initiated before our consultation; all would have been eligible to participate in the protocol. Follow-up extended through April 1, 1991. RESULTS: Group A had a significantly prolonged time to recurrence (median, 41 months) compared with group R (median, 10 months; P = .003). Although median survival was doubled from 21.7 months for group R to 42.5 months for group A, this was not statistically significant because of small sample size. More importantly, group R patients received systemic chemotherapy for recurrent PCNSL, which improved survival. CONCLUSION: The addition of chemotherapy to cranial RT for initial treatment of PCNSL significantly improved disease-free survival and contributed to overall survival; all non-AIDS patients with newly diagnosed PCNSL should be considered for combined modality therapy.

This article has been cited by other articles:

				G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Ann. Onc., October 26, 2008; (2008) mdn628v1. [Abstract] [Full Text] [PDF]

				S. A. Grimm, C. A. McCannel, A.M.P. Omuro, A. J.M. Ferreri, J. -Y. Blay, E. A. Neuwelt, T. Siegal, T. Batchelor, K. Jahnke, T. N. Shenkier, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report Neurology, October 21, 2008; 71(17): 1355 - 1360. [Abstract] [Full Text] [PDF]

				R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, N. Yajima, T. Tamura, H. Hondoh, H. Takahashi, et al. Results of Treatment of 112 Cases of Primary CNS Lymphoma Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 373 - 380. [Abstract] [Full Text] [PDF]

				N. A. Mohile, L. M. DeAngelis, and L. E. Abrey The utility of body FDG PET in staging primary central nervous system lymphoma Neuro-oncol, April 1, 2008; 10(2): 223 - 228. [Abstract] [Full Text] [PDF]

				M Montemurro, T Kiefer, F Schuler, H. Al-Ali, H-H Wolf, R Herbst, A Haas, K Helke, A Theilig, C Lotze, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study Ann. Onc., April 1, 2007; 18(4): 665 - 671. [Abstract] [Full Text] [PDF]

				A. Lobo, N. Okhravi, P. Adamson, B. J Clark, and S. Lightman Protocol for the Use of Polymerase Chain Reaction in the Detection of Intraocular Large B-Cell Lymphoma in Ocular Samples J. Mol. Diagn., February 1, 2007; 9(1): 113 - 121. [Abstract] [Full Text] [PDF]

				E. T. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s. [Abstract] [Full Text] [PDF]

				L. E. Abrey, T. T. Batchelor, A. J.M. Ferreri, M. Gospodarowicz, E. J. Pulczynski, E. Zucca, J. R. Smith, A. Korfel, C. Soussain, L. M. DeAngelis, et al. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 5034 - 5043. [Abstract] [Full Text] [PDF]

				A. M.P. Omuro, L. M. DeAngelis, J. Yahalom, and L. E. Abrey Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up Neurology, January 11, 2005; 64(1): 69 - 74. [Abstract] [Full Text] [PDF]

				L. Fischer, E. Thiel, H. A. Klasen, H. Kirchen, K. Jahnke, and A. Korfel Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan Neurology, May 25, 2004; 62(10): 1885 - 1887. [Abstract] [Full Text] [PDF]

				H. Harder, H. Holtel, J. E.C. Bromberg, P. Poortmans, H. Haaxma-Reiche, H. C. Kluin-Nelemans, J. Menten, and M. J. van den Bent Cognitive status and quality of life after treatment for primary CNS lymphoma Neurology, February 24, 2004; 62(4): 544 - 547. [Abstract] [Full Text] [PDF]

				D. D. Correa, L. M. DeAngelis, W. Shi, H. Thaler, A. Glass, and L. E. Abrey Cognitive functions in survivors of primary central nervous system lymphoma Neurology, February 24, 2004; 62(4): 548 - 555. [Abstract] [Full Text] [PDF]

				H. Pels, I. G.H. Schmidt-Wolf, A. Glasmacher, H. Schulz, A. Engert, V. Diehl, A. Zellner, G. Schackert, H. Reichmann, F. Kroschinsky, et al. Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy J. Clin. Oncol., December 15, 2003; 21(24): 4489 - 4495. [Abstract] [Full Text] [PDF]

				V. S. Lima, E. B. Leite, R. P. Fonseca, and A. S. Fernandes Jr Patients Presenting With CNS Lesions: CASE 1. PRIMARY LOW-GRADE MUCOSA-ASSOCIATED B-CELL LYMPHOMA OF THE DURA J. Clin. Oncol., November 1, 2003; 21(21): 4058 - 4060. [Full Text] [PDF]

				H. Ishikawa, M. Hasegawa, Y. Tamaki, K. Hayakawa, T. Akimoto, H. Sakurai, N. Mitsuhashi, H. Niibe, M. Tamura, and T. Nakano Comparable Outcomes of Radiation Therapy without High-dose Methotrexate for Patients with Primary Central Nervous System Lymphoma Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 443 - 449. [Abstract] [Full Text] [PDF]

				K. Hoang-Xuan, L. Taillandier, O. Chinot, P. Soubeyran, U. Bogdhan, J. Hildebrand, M. Frenay, N. De Beule, J.Y. Delattre, and B. Baron Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group J. Clin. Oncol., July 15, 2003; 21(14): 2726 - 2731. [Abstract] [Full Text] [PDF]

				K. Fliessbach, H. Urbach, C. Helmstaedter, H. Pels, A. Glasmacher, J. A. Kraus, T. Klockgether, I. Schmidt-Wolf, and U. Schlegel Cognitive Performance and Magnetic Resonance Imaging Findings After High-Dose Systemic and Intraventricular Chemotherapy for Primary Central Nervous System Lymphoma Arch Neurol, April 1, 2003; 60(4): 563 - 568. [Abstract] [Full Text] [PDF]

				L. M. DeAngelis, W. Seiferheld, S. C. Schold, B. Fisher, and C. J. Schultz Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10 J. Clin. Oncol., December 15, 2002; 20(24): 4643 - 4648. [Abstract] [Full Text] [PDF]

				A multicenter study of treatment of primary CNS lymphoma Neurology, May 28, 2002; 58(10): 1513 - 1520.

				P N Shams, A Waldman, and G T Plant B Cell lymphoma of the brain stem masquerading as myasthenia J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 271 - 273. [Abstract] [Full Text] [PDF]

				A. Lister, L. E. Abrey, and J. T. Sandlund Central Nervous System Lymphoma Hematology, January 1, 2002; 2002(1): 283 - 296. [Abstract] [Full Text]

				L Ayuso-Peralta, M Orti-Pareja, M Zurdo-Hernandez, F J Jimenez-Jimenez, J Tejeiro-Martinez, J R Ricoy, A de la Lama, and A I Bernardo Cerebral lymphoma presenting as a leukoencephalopathy J. Neurol. Neurosurg. Psychiatry, August 1, 2001; 71(2): 243 - 246. [Abstract] [Full Text] [PDF]

				U Schlegel, H Pels, A Glasmacher, R Kleinschmidt, I Schmidt-Wolf, C Helmstaedter, K Fliessbach, M Deckert, D Van Roost, R Fimmers, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 118 - 122. [Abstract] [Full Text] [PDF]

				J. Hochman, N. Assaf, M. Deckert-Schluter, O. D. Wiestler, and J. Pe'er Entry Routes of Malignant Lymphoma into the Brain and Eyes in a Mouse Model Cancer Res., July 1, 2001; 61(13): 5242 - 5247. [Abstract] [Full Text] [PDF]

				C. Soussain, F. Suzan, K. Hoang-Xuan, N. Cassoux, V. Levy, N. Azar, C. Belanger, E. Achour, V. Ribrag, S. Gerber, et al. Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma J. Clin. Oncol., February 1, 2001; 19(3): 742 - 749. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]

				M-F. Mamzer-Bruneel, C. Lome, E. Morelon, V. Levy, P. Bourquelot, F. Jacobs, A. Gessain, E. Mac Intyre, N. Brousse, H. Kreis, et al. Durable Remission After Aggressive Chemotherapy for Very Late Post-Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center J. Clin. Oncol., November 1, 2000; 18(21): 3622 - 3632. [Abstract] [Full Text] [PDF]

				C. Cursiefen, L. M. Holbach, B. Lafaut, K. Heimann, T. Kirchner, and G. O. H. Naumann Oculocerebral Non-Hodgkin's Lymphoma With Uveal Involvement: Development of an Epibulbar Tumor After Vitrectomy Arch Ophthalmol, October 1, 2000; 118(10): 1437 - 1440. [Abstract] [Full Text] [PDF]

				L. E. Abrey, J. Yahalom, and L. M. DeAngelis Treatment for Primary CNS Lymphoma: The Next Step J. Clin. Oncol., September 17, 2000; 18(17): 3144 - 3150. [Abstract] [Full Text] [PDF]

				U. Herrlinger, W. Brugger, M. Bamberg, W. Kuker, J. Dichgans, and M. Weller PCV salvage chemotherapy for recurrent primary CNS lymphoma Neurology, April 25, 2000; 54(8): 1707 - 1708. [Full Text] [PDF]

				H. A. Fine, W. D. Figg, K. Jaeckle, P. Y. Wen, A. P. Kyritsis, J. S. Loeffler, V. A. Levin, P. M. Black, R. Kaplan, J. M. Pluda, et al. Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas J. Clin. Oncol., February 14, 2000; 18(4): 708 - 708. [Abstract] [Full Text] [PDF]

				S. Ng, M. A. Rosenthal, D. Ashley, and L. Cher High-dose methotrexate for primary CNS lymphoma in the elderly Neuro-oncol, January 1, 2000; 2(1): 40 - 44. [Abstract] [PDF]

				L. M DeANGELIS Primary central nervous system lymphoma J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 699 - 701. [Full Text]

				M. D de Smet, V. S. Vancs, D. Kohler, D. Solomon, and C. C. Chan Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma Br. J. Ophthalmol., April 1, 1999; 83(4): 448 - 451. [Abstract] [Full Text]